ZA962753B - 1,3-Dihydro-2H-imidazol-2-one derivatives. - Google Patents

1,3-Dihydro-2H-imidazol-2-one derivatives.

Info

Publication number
ZA962753B
ZA962753B ZA9602753A ZA962753A ZA962753B ZA 962753 B ZA962753 B ZA 962753B ZA 9602753 A ZA9602753 A ZA 9602753A ZA 962753 A ZA962753 A ZA 962753A ZA 962753 B ZA962753 B ZA 962753B
Authority
ZA
South Africa
Prior art keywords
imidazol
dihydro
derivatives
Prior art date
Application number
ZA9602753A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Gaston Stanislas Marcell Diels
Jose Ignacio Andres-Gil
Francisco Javi Fernandez-Gadea
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA962753B publication Critical patent/ZA962753B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9602753A 1995-04-06 1996-04-04 1,3-Dihydro-2H-imidazol-2-one derivatives. ZA962753B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95200870 1995-04-06

Publications (1)

Publication Number Publication Date
ZA962753B true ZA962753B (en) 1997-10-06

Family

ID=8220175

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9602753A ZA962753B (en) 1995-04-06 1996-04-04 1,3-Dihydro-2H-imidazol-2-one derivatives.

Country Status (15)

Country Link
US (1) US5869515A (xx)
EP (1) EP0832071B1 (xx)
JP (1) JP4115519B2 (xx)
KR (1) KR100400159B1 (xx)
CN (1) CN1103760C (xx)
AR (1) AR002984A1 (xx)
AT (1) ATE305455T1 (xx)
CA (1) CA2216542C (xx)
DE (1) DE69635224T2 (xx)
ES (1) ES2250988T3 (xx)
IL (1) IL117806A (xx)
MY (1) MY117936A (xx)
TW (1) TW375612B (xx)
WO (1) WO1996031487A1 (xx)
ZA (1) ZA962753B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
SK285878B6 (sk) * 1996-10-02 2007-10-04 Janssen Pharmaceutica N. V. Derivát 2-kyaniminoimidazolu, prostriedok obsahujúci tento derivát, spôsob prípravy tohto prostriedku, uvedený derivát na použitie ako liečivo, použitie tohto derivátu na prípravu liečiva a spôsob prípravy tohto derivátu
SK284468B6 (sk) * 1998-04-01 2005-04-01 Janssen Pharmaceutica N. V. Pyridínový derivát, spôsob jeho prípravy a použitie, kompozícia s jeho obsahom a spôsob jej prípravy
PT1212089E (pt) 1999-08-21 2006-08-31 Altana Pharma Ag Combinacao sinergica de roflumilast e salmeterol
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
MXPA06012505A (es) 2004-04-30 2006-12-15 Warner Lambert Co Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central.
US20080070867A1 (en) * 2005-01-19 2008-03-20 Metabasis Therapeutics, Inc. 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases
JP2009525269A (ja) * 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
CA1309096C (en) * 1985-08-13 1992-10-20 Sumitomo Chemical Co., Ltd. Butenoic acid derivatives, and their production and use
US4845233A (en) * 1987-09-11 1989-07-04 Iprx, Inc. Imidazolin-2-ones
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
ATE282025T1 (de) * 1992-07-28 2004-11-15 Aventis Pharma Ltd Inhibitoren von c-amp phosphodiesterase
EP0711282B1 (en) * 1993-07-28 2002-06-05 Aventis Pharma Limited Compounds as pde iv and tnf inhibitors
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
CA2193725A1 (en) * 1994-06-24 1996-01-04 David Cavalla Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity

Also Published As

Publication number Publication date
TW375612B (en) 1999-12-01
AU697390B2 (en) 1998-10-01
IL117806A0 (en) 1996-08-04
KR19980703448A (ko) 1998-11-05
ES2250988T3 (es) 2006-04-16
CN1103760C (zh) 2003-03-26
EP0832071B1 (en) 2005-09-28
ATE305455T1 (de) 2005-10-15
DE69635224T2 (de) 2006-06-22
IL117806A (en) 2000-02-17
MY117936A (en) 2004-08-30
CN1181073A (zh) 1998-05-06
DE69635224D1 (de) 2006-02-09
CA2216542C (en) 2009-01-13
CA2216542A1 (en) 1996-10-10
AR002984A1 (es) 1998-05-27
WO1996031487A1 (en) 1996-10-10
EP0832071A1 (en) 1998-04-01
JPH11504003A (ja) 1999-04-06
AU5497996A (en) 1996-10-23
US5869515A (en) 1999-02-09
JP4115519B2 (ja) 2008-07-09
KR100400159B1 (ko) 2003-12-31

Similar Documents

Publication Publication Date Title
ZA961444B (en) Pyrazolylbenzoyl derivatives.
HRP970454B1 (en) Substituted 6,5-hetero-bicyclic derivatives
HK1019597A1 (en) Substituted 6, 6-hetero-bicyclic derivatives
MX213417B (es) Fenilpiridazinonas.
HK1010196A1 (en) Novel 2,3-dioxo-1,2,3,4-tetrahdro-quinoyxalinyl derivatives.
ZA961449B (en) Isoxazolylbenzoyl derivatives.
ZA961955B (en) Indazolecarboxamides.
EP0845457A4 (en) 2,2-DIDEUTERO-5-AMINOLEVULINIC ACID
ZA969973B (en) 2-thioxo-imidazolidin-4-one derivatives.
AU6123196A (en) N-aryl-1,2,4-triazolin-5-ones
ZA973984B (en) 2,4-diaminopyrimidine derivatives.
DE69610844D1 (en) Hydroformylierungsverfahren.
ZA945238B (en) 1,5 Benzodiazepine derivatives.
ZA962755B (en) 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives.
ZA967741B (en) Diarylalkenylamine derivatives.
ZA962753B (en) 1,3-Dihydro-2H-imidazol-2-one derivatives.
ZA962821B (en) 4-indolylpiperazinyl derivatives.
ZA969625B (en) 25-Hydroxy-16-ene-26, 27-bishomo-cholecalciferols
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
ZA965465B (en) 2,4,5-Trisubstituted phenylketoenois
ZA972302B (en) 1,25-Dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives.
ZA964034B (en) N-aminopyridone derivatives.
ZA965713B (en) 5-pyrazolylbenzoic acid derivatives.
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
ZA964692B (en) Benzimidazole derivatives.